Our approach for targeting cancer


Our technology is a cutting edge bispecific antibody designed to

  • Be directly administered to patients through injection, ensuring a precise and controlled delivery.
  • Accurately target and bind to a specific component of the human innate immune complex (HIIC), a natural part of the body's defense mechanism, circulating within the bloodstream.
  • Navigate this bound immune complex towards cancer cells, utilizing the ability to recognize and attach to specific markers present only on the surface of these cells.
  • Significantly increase the concentration of the HIIC within cancer cells, triggering a focused and effective destruction of the malignant cells.